IL219314A0 - Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors - Google Patents

Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors

Info

Publication number
IL219314A0
IL219314A0 IL219314A IL21931412A IL219314A0 IL 219314 A0 IL219314 A0 IL 219314A0 IL 219314 A IL219314 A IL 219314A IL 21931412 A IL21931412 A IL 21931412A IL 219314 A0 IL219314 A0 IL 219314A0
Authority
IL
Israel
Prior art keywords
carbamoylmethylamino
substituted
acetic acid
acid derivatives
nep inhibitors
Prior art date
Application number
IL219314A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL219314A0 publication Critical patent/IL219314A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
IL219314A 2009-11-20 2012-04-19 Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors IL219314A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26313709P 2009-11-20 2009-11-20
US35991410P 2010-06-30 2010-06-30
PCT/EP2010/067781 WO2011061271A1 (en) 2009-11-20 2010-11-18 Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors

Publications (1)

Publication Number Publication Date
IL219314A0 true IL219314A0 (en) 2012-06-28

Family

ID=43431937

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219314A IL219314A0 (en) 2009-11-20 2012-04-19 Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors

Country Status (37)

Country Link
US (4) US8222286B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EP (2) EP2735561B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP (2) JP5543609B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
KR (1) KR101460421B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN (1) CN102666493B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AR (1) AR079061A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AU (1) AU2010320930B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BR (1) BR112012011977A2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CA (1) CA2780150C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CL (1) CL2012001298A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CO (1) CO6540001A2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CR (1) CR20120237A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DK (1) DK2501683T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EA (1) EA021479B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EC (1) ECSP12011978A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ES (2) ES2481890T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
GT (1) GT201200153A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HN (1) HN2012001037A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HR (1) HRP20140691T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IL (1) IL219314A0 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IN (1) IN2012DN02465A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JO (1) JO2967B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MA (1) MA33886B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MX (1) MX2012005813A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MY (1) MY158299A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NZ (1) NZ599136A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PE (1) PE20121311A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PH (1) PH12012500519A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PL (1) PL2501683T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PT (1) PT2501683E (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
RS (1) RS53422B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SI (1) SI2501683T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TN (1) TN2012000125A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TW (1) TWI481598B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
UY (1) UY33044A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
WO (1) WO2011061271A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ZA (1) ZA201202018B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
KR101442897B1 (ko) * 2009-05-28 2014-09-23 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
EP2651896B1 (en) 2010-12-15 2015-08-12 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
AU2011343903B2 (en) 2010-12-15 2016-06-30 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
SG192815A1 (en) 2011-02-17 2013-09-30 Theravance Inc Substituted aminobutyric derivatives as neprilysin inhibitors
WO2012154249A1 (en) 2011-02-17 2012-11-15 Theravance, Inc. Substituted aminobutyric derivatives as neprilysin inhibitors
CN103596928B (zh) 2011-05-31 2017-02-15 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
WO2012166389A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
ES2699773T3 (es) 2011-05-31 2019-02-12 Theravance Biopharma R&D Ip Llc Inhibidores de neprilisina
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
CN104350052B (zh) 2012-05-31 2017-05-31 施万生物制药研发Ip有限责任公司 一氧化氮供体脑啡肽酶抑制剂
CA2873328A1 (en) 2012-06-08 2013-12-12 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
AU2013271537B2 (en) 2012-06-08 2017-05-11 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
ES2615275T3 (es) 2012-08-08 2017-06-06 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN105008337B (zh) 2013-02-14 2017-08-04 诺华股份有限公司 具有改善的体内功效的作为nep抑制剂的取代的联苯基丁酸衍生物
BR112015019369A2 (pt) * 2013-02-14 2017-07-18 Novartis Ag derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra)
SI2964616T1 (sl) 2013-03-05 2017-08-31 Theravance Biopharma R&D Ip, Llc Zaviralci neprilizina
PE20160878A1 (es) 2013-07-25 2016-09-08 Novartis Ag Polipeptidos ciclicos para el tratamiento de la insuficiencia cardiaca
TW201518323A (zh) 2013-07-25 2015-05-16 Novartis Ag 合成ａｐｅｌｉｎ多肽之生物結合物
CN105992763A (zh) 2014-01-30 2016-10-05 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
SG11201606057PA (en) 2014-01-30 2016-08-30 Theravance Biopharma R&D Ip Llc 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
WO2016116842A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
WO2016130650A1 (en) 2015-02-11 2016-08-18 Theravance Biopharma R&D Ip, Llc (2s, 4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
LT3259255T (lt) 2015-02-19 2021-04-26 Theravance Biopharma R&D Ip, Llc (2r,4r)-5-(5`-chlor-2`-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentano rūgštis
CA3015505C (en) 2016-03-08 2024-03-05 Theravance Biopharma R&D Ip, Llc Crystalline (2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
US12168643B2 (en) 2019-06-19 2024-12-17 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188162C (nl) * 1978-11-25 1992-04-16 Nippon Kayaku Kk Werkwijze voor het bereiden van een bestatinederivaat.
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
GB2074571B (en) 1980-04-11 1984-02-15 Wellcome Found Alpha-benzyl-substituted amides
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4610816A (en) * 1980-12-18 1986-09-09 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4721726A (en) * 1980-12-18 1988-01-26 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
IE53315B1 (en) * 1980-12-18 1988-10-12 Schering Corp Substituted dipeptides,processes for their preparation and pharmaceutical compositions containing them and their use in the inhibition of enkephalinase
JPS5865260A (ja) 1981-10-13 1983-04-18 Microbial Chem Res Found ３−アミノ−２−ヒドロキシ−４−フエニル酪酸誘導体および医薬組成物
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
DE3376649D1 (en) 1982-06-17 1988-06-23 Schering Corp Substituted dipeptides, methods for their production, pharmaceutical compositions containing them, method for making such pharmaceutical compositions
NZ201001A (en) * 1982-06-17 1986-02-21 Schering Corp Substituted dipeptide derivatives and method of preparation
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
AU569719B2 (en) 1983-01-28 1988-02-18 Schering Corporation Phosphorous compounds as inhibitors of enkephalinases
FI77669C (fi) 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
EP0136883B1 (en) 1983-10-03 1987-11-25 E.R. Squibb & Sons, Inc. Enkephalinase inhibitors
DE3347565A1 (de) 1983-12-30 1985-07-11 Thomae Gmbh Dr K Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPS60248659A (ja) * 1984-05-25 1985-12-09 Microbial Chem Res Found ３−〔ｎ−（メルカプトアシル）〕アミノ−４−アリ−ル酪酸誘導体及びそれを有効成分とする鎮痛剤
JPS6354321A (ja) 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
FR2597865B1 (fr) 1986-04-29 1990-11-09 Roussel Uclaf Nouveaux derives d'un acide benzyl alkyl carboxylique substitue par un radical 4-pyridinyl aminocarbonyle, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
FR2605004B1 (fr) 1986-09-25 1989-01-13 Centre Nat Rech Scient Nouveaux derives d'amino-acides, leur procede de preparation et composition pharmaceutiques les contenant
CA1337400C (en) 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
JP2848411B2 (ja) * 1988-08-18 1999-01-20 サイオス インコーポレイテッド 心房性ナトリウム利尿ペプチドクリアランス阻害剤
FR2651229B1 (fr) 1989-08-24 1991-12-13 Inst Nat Sante Rech Med Nouveaux derives d'amino-acides, leur procede de preparation et leur application therapeutique.
FR2652087B1 (fr) * 1989-09-15 1993-10-15 Bioprojet Ste Civile Derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques.
AU7168091A (en) 1989-12-22 1991-07-24 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
EP0512042B1 (en) 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
US5223516A (en) * 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
US5200426A (en) * 1990-08-14 1993-04-06 Board Of Regents, The University Of Texas Inhibitors of neutral endopeptidase/CALLA as chemotherapeutic agents
JPH04149166A (ja) 1990-10-12 1992-05-22 Nippon Kayaku Co Ltd 新規ケト酸アミド誘導体
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
AU654331B2 (en) 1991-03-30 1994-11-03 Kissei Pharmaceutical Co. Ltd. Succinic acid compounds
US5294632A (en) * 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
AU660930B2 (en) 1991-06-21 1995-07-13 Novo Nordisk A/S (S)(+)-2-ethoxy-4-(N-(1-(2-piperidinophenyl)-3-methyl-1- butyl)aminocarbonylmethyl)benzoic acid
GB9114006D0 (en) 1991-06-28 1991-08-14 Fujisawa Pharmaceutical Co New propionamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
DE10199058I2 (de) 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
EP0533130A1 (de) 1991-09-19 1993-03-24 Hoechst Aktiengesellschaft 2-Hydroxymethylpyridine, die entsprechenden Pyridin-N-oxide und ihre Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung
CA2078759C (en) 1991-09-27 2003-09-16 Alan M. Warshawsky Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
US5273990A (en) * 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
US5250522A (en) * 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
JPH06234630A (ja) 1992-12-17 1994-08-23 Tanabe Seiyaku Co Ltd 中性メタロエンドペプチダーゼ阻害剤
AU6267894A (en) 1993-03-02 1994-09-26 G.D. Searle & Co. N-acyl beta amino acid derivatives useful as platelet aggregation inhibitors
JP3576193B2 (ja) 1993-12-03 2004-10-13 第一製薬株式会社 ビフェニルメチル置換バレリルアミド誘導体
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5517996A (en) * 1994-04-21 1996-05-21 Hitachi Medical Corporation Ultrasonic diagnostic apparatus
IT1270261B (it) 1994-06-21 1997-04-29 Zambon Spa Derivati peptidici ad attivita' inibitrice delle metallopeptidasi
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
CN1055681C (zh) * 1994-11-04 2000-08-23 参天制药株式会社 带有羟基的新1,3－二烷基脲衍生物
DE69528197T2 (de) * 1994-12-14 2003-06-05 Santen Pharmaceutical Co., Ltd Neue 1,3-dialkylharnstoff-derivate
TW313568B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 1994-12-20 1997-08-21 Hoffmann La Roche
US5550119A (en) * 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
US5703092A (en) * 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
US5710171A (en) * 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
IL118657A0 (en) 1996-06-14 1996-10-16 Arad Dorit Inhibitors for picornavirus proteases
EP0927156A1 (en) 1996-09-04 1999-07-07 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
FR2755135B1 (fr) 1996-10-25 2002-12-27 Inst Nat Sante Rech Med Nouveaux derives d'(alpha-aminophosphino)peptides, leur procede de preparation et les compositions qui les contiennent
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
ATE318841T1 (de) 1997-05-29 2006-03-15 Merck & Co Inc Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
WO1999026923A1 (en) 1997-11-20 1999-06-03 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
WO1999026922A1 (en) 1997-11-21 1999-06-03 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
DE69824037T2 (de) 1997-11-24 2005-06-02 Merck & Co., Inc. Beta-alanin-derivate als zell-adhäsions-inhibitoren
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6169103B1 (en) * 1998-03-03 2001-01-02 Warner-Lambert Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
JP4070357B2 (ja) 1999-06-03 2008-04-02 花王株式会社 皮膚外用剤
GB2354440A (en) 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
US6803388B2 (en) 1999-09-23 2004-10-12 Pfizer, Inc. (R)-Chiral halogenated substituted n,n-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US6509330B2 (en) * 2000-02-17 2003-01-21 Bristol-Myers Squibb Company Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors
RU2002129569A (ru) 2000-04-12 2004-03-27 Новартис АГ (CH) Новое медицинское применение ингибиторов альдостеронсинтазы индивидуально или в сочетании с антагонистами ат1-рецептора
ES2257441T3 (es) 2000-09-29 2006-08-01 Topotarget Uk Limited Compuestos de acido carbonico que comprenden un enlace amino como inhibidores hdac.
ATE370732T1 (de) 2002-01-17 2007-09-15 Novartis Pharma Gmbh Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP4233353B2 (ja) 2002-02-27 2009-03-04 田辺三菱製薬株式会社 医薬組成物
US20040063761A1 (en) * 2002-08-06 2004-04-01 Kuduk Scott D. 2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridine derivatives
US7732603B2 (en) 2002-08-07 2010-06-08 Novartis Ag Organic compounds as agents for the treatment of aldosterone mediated conditions
BR0316306A (pt) 2002-11-18 2005-09-27 Novartis Ag Compostos orgânicos
US20040142379A1 (en) 2003-01-16 2004-07-22 Carlsberg Research Laboratory Affinity fishing for ligands and proteins receptors
RS20050814A (en) 2003-04-30 2008-04-04 The Institutes For Pharmaceutical Discovery, Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EP1664001A2 (en) 2003-07-29 2006-06-07 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same
WO2005014534A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TW200611898A (en) 2004-05-28 2006-04-16 Speedel Experimenta Ag Organic compounds
JP5179174B2 (ja) 2004-05-28 2013-04-10 ノバルティス ファーマ アーゲー アルドステロンシンターゼ阻害剤としてのテトラヒドロ−イミダゾ［１，５−ａ］ピリジン誘導体
WO2005118541A2 (en) 2004-05-28 2005-12-15 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
WO2006005726A2 (en) 2004-07-09 2006-01-19 Speedel Experimenta Ag Heterocyclic compounds
US20070265345A1 (en) 2004-07-27 2007-11-15 Smithkline Beecham Corporation Novel Biphenyl Compounds And Their Use
WO2006015885A1 (en) 2004-08-13 2006-02-16 University College Dublin, National University Of Ireland, Dublin Amino acid dehydrogenase-derived biocatalysts
EP1814869A2 (en) 2004-11-18 2007-08-08 The Institutes for Pharmaceutical Discovery, LLC Substituted amino acids as protein tyrosine phosphatase inhibitors
WO2006069096A1 (en) 2004-12-20 2006-06-29 Pharmacyclics, Inc. Silanol derivatives as inhibitors of histone deacetylase
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
WO2007045663A2 (en) 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
JP2009514961A (ja) 2005-11-08 2009-04-09 ノバルティス アクチエンゲゼルシャフト アンギオテンシンｉｉ受容体ブロッカー、カルシウムチャネルブロッカーおよび他の活性剤の組合せ
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
TW200804378A (en) 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
EP2009080A4 (en) 2006-04-04 2010-05-26 Taiyo Nippon Sanso Corp METHOD OF REMOVING METHANE, METHANE PARATOR AND METHOD USE SYSTEM
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
WO2008073138A2 (en) 2006-05-15 2008-06-19 Irm Llc Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
BRPI0715938A2 (pt) 2006-08-25 2014-05-20 Novartis Ag Derivados de imidazol fundidos para o tratamento de distúrbios mediados por aldosterona sintase e/ou 11-beta-hidroxilase e/ou aromatase
EP1903027A1 (en) 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
EP2121652A1 (en) 2006-12-18 2009-11-25 Novartis AG 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
WO2008076862A2 (en) 2006-12-18 2008-06-26 Novartis Ag 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
AU2007334416A1 (en) 2006-12-18 2008-06-26 Novartis Ag Imidazoles as aldosterone synthase inhibitors
PL2121578T3 (pl) 2007-01-12 2017-02-28 Novartis Ag Sposób wytwarzania kwasu 5-bifenyl-4-amino-2-metylo-pentanowego
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TW200904416A (en) 2007-03-29 2009-02-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
US8980833B2 (en) 2007-05-10 2015-03-17 R&D-Biopharmaceuticals Gmbh Tubulysine derivatives
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
MY153730A (en) 2007-11-06 2015-03-13 Novartis Ag Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
ES2385773T3 (es) 2007-12-11 2012-07-31 Theravance, Inc. Derivados de benzoimidazol, de doble acción, y su utilización como agentes antihipertensivos
EP2070928A1 (en) 2007-12-12 2009-06-17 NERVIANO MEDICAL SCIENCES S.r.l. 7-azaindol-3-ylacrylamides active as kinase inhibitors
PE20091364A1 (es) 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
US7863309B2 (en) 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
KR101442897B1 (ko) * 2009-05-28 2014-09-23 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체
EP2435402B1 (en) * 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
RU2534619C2 (ru) 2009-09-23 2014-11-27 Чжэцзян Цзючжоу Фармасьютикл Ко., Лтд. Способ получения n-ацилбифенилаланина
JO2967B1 (en) * 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors

Also Published As

Publication number Publication date
EA021479B1 (ru) 2015-06-30
IN2012DN02465A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2015-08-21
US20140088165A1 (en) 2014-03-27
EP2501683B1 (en) 2014-04-23
JP2014167015A (ja) 2014-09-11
JP5543609B2 (ja) 2014-07-09
US8877786B2 (en) 2014-11-04
US20120202862A1 (en) 2012-08-09
CN102666493A (zh) 2012-09-12
HN2012001037A (es) 2015-08-10
CO6540001A2 (es) 2012-10-16
US20110124695A1 (en) 2011-05-26
US8377978B2 (en) 2013-02-19
CA2780150A1 (en) 2011-05-26
AU2010320930B2 (en) 2014-05-15
HRP20140691T1 (hr) 2014-10-24
SI2501683T1 (sl) 2014-07-31
EP2735561B1 (en) 2016-07-20
ES2598961T3 (es) 2017-01-30
EP2501683A1 (en) 2012-09-26
CA2780150C (en) 2017-10-17
MA33886B1 (fr) 2013-01-02
US8642635B2 (en) 2014-02-04
PT2501683E (pt) 2014-07-24
ECSP12011978A (es) 2012-07-31
TW201121949A (en) 2011-07-01
TWI481598B (zh) 2015-04-21
MY158299A (en) 2016-09-30
US20130096168A1 (en) 2013-04-18
EA201200763A1 (ru) 2012-12-28
CL2012001298A1 (es) 2012-10-05
ES2481890T3 (es) 2014-07-31
BR112012011977A2 (pt) 2020-09-08
GT201200153A (es) 2014-12-30
US8222286B2 (en) 2012-07-17
WO2011061271A1 (en) 2011-05-26
NZ599136A (en) 2013-07-26
PH12012500519A1 (en) 2012-10-22
JP2013510835A (ja) 2013-03-28
PE20121311A1 (es) 2012-10-12
HK1170475A1 (en) 2013-03-01
PL2501683T3 (pl) 2014-09-30
CN102666493B (zh) 2015-09-23
KR20120084327A (ko) 2012-07-27
KR101460421B1 (ko) 2014-11-10
AR079061A1 (es) 2011-12-21
CR20120237A (es) 2012-06-07
ZA201202018B (en) 2012-11-28
TN2012000125A1 (en) 2013-09-19
MX2012005813A (es) 2012-06-12
DK2501683T3 (da) 2014-06-30
RS53422B (en) 2014-12-31
AU2010320930A1 (en) 2012-04-12
JO2967B1 (en) 2016-03-15
EP2735561A1 (en) 2014-05-28
UY33044A (es) 2011-06-30

Similar Documents

Publication Publication Date Title
IL219314A0 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
ZA201203615B (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
LT3037089T (lt) Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
IL215691A0 (en) Carboxylic acid compound
ZA201008096B (en) Carboxylic acid compound
IL214446A0 (en) Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
EP2330894A4 (en) COMPOSITIONS COMPRISING 6-AMINO-HEXAXIDE ACID DERIVATIVES AS HDAC INHIBITORS
SI2512474T1 (sl) N-vezani derivati hidroksamske kisline, uporabni kot protibakterijska sredstva
ZA201201124B (en) Heterocyclic compounds as autotaxin inhibitors
ZA201107986B (en) Heterocyclic compounds as autotaxin inhibitors
HUE042839T2 (hu) Piridilaminoecetsav vegyületek
PL2178840T3 (pl) Pochodne kwasu azabifenyloaminobenzoesowego jako inhibitory dhodh
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
ZA201007184B (en) Cyclopentylacrylic acid amide derivative
IL217001A0 (en) Preparation of substituted 2-fluoroacrylic acid derivatives
IL218967A0 (en) Phenyloxadiazole derivatives as pgds inhibitors
EP2542232A4 (en) FATTY ACID INHIBITORS
IL206524A0 (en) 4-dimethylminobutyric acid derivatives
ZA201102450B (en) Amino acid derivative
PL2470171T3 (pl) Przeciwdrobnoustrojowe pochodne kwasu aminosalicylowego
GB0921967D0 (en) Novel Aryloxyanilide Derivatives
GB0906872D0 (en) Amino acid derivatives
HK1162510A (en) 7-phenoxychroman carboxylic acid derivatives
GB201014094D0 (en) Amino acid derivatives
GB201009520D0 (en) Amino acid derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees